United States Lymph Cancer Testing Market Booms | AI & Precision Diagnostics Drive 11.3% CAGR

Leander, Texas, United States - Dec.17.2025
As per DataM Intelligence research report "Global Lymph Cancer Testing Market reached USD 8.5 billion in 2023 and is expected to reach USD 19.63 billion by 2031, growing with a CAGR of 11.3% from 2024 to 2031.". Advancements in diagnostic technologies are driving the development of precise and early lymph cancer testing solutions.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/lymph-cancer-testing-market?sindhuri

Lymph Cancer Testing Market: Recent Industry Developments
United States: Recent Industry Developments
✅ In November 2025, Foresight Diagnostics presented multiple studies at the ASH Annual Meeting featuring PhasED-SeqTM ultrasensitive MRD analysis for lymphoma, highlighting improved prognostic accuracy in large B-cell lymphoma and integration into clinical trials.
✅ In October 2025, Roche expanded its lymphoma diagnostics portfolio with advanced assays supporting B-cell lymphoma detection and personalized treatment monitoring.
✅ In September 2025, Abbott Laboratories advanced blood-based testing platforms for non-Hodgkin lymphoma, enhancing biomarker detection and early diagnosis capabilities.
✅ In August 2025, Siemens Healthineers introduced AI-enhanced imaging and molecular diagnostics for lymph cancer, improving accuracy in staging and monitoring.

Japan: Recent Industry Developments
✅ In November 2025, Genmab A/S received approval from Japan's Ministry of Health for EPKINLY (epcoritamab) in relapsed/refractory follicular lymphoma, supported by advanced diagnostic companion testing.
✅ In October 2025, Canon Medical Systems invested in next-generation sequencing tools for lymphoma molecular diagnostics targeting Japanese coastal and urban populations.
✅ In September 2025, Agilent Technologies deployed hybrid genomic testing units for lymphoma in pilot projects across Japan, focusing on high-sensitivity mutation detection.
✅ In August 2025, Bio-Rad Laboratories initiated renewable AI-driven diagnostic projects for lymph cancer testing, integrating NGS and flow cytometry for enhanced precision.

Lymph Cancer Testing Market: Drivers
The lymph cancer testing market is experiencing robust growth due to the rising prevalence of lymphomas worldwide, including non-Hodgkin and Hodgkin types, alongside increasing demand for early and accurate diagnosis. Technological advancements in imaging (CT/PET scans), biopsy techniques, blood tests, and molecular diagnostics like next-generation sequencing are improving detection rates, enabling personalized treatment, and reducing diagnostic timelines. Growing awareness of cancer screening, supportive government initiatives for oncology research, and the integration of AI and automation in pathology are further accelerating market expansion.
Collaboration among diagnostic companies, hospitals, and research institutions is fostering innovation in biomarker identification, minimal residual disease monitoring, and companion diagnostics. The shift toward precision medicine, liquid biopsies, and non-invasive testing is enhancing patient outcomes in both developed and emerging regions. With an aging global population, higher incidence rates, and investments in healthcare infrastructure, the lymph cancer testing market is positioned for sustained growth, addressing critical needs in oncology care.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/lymph-cancer-testing-market?sindhuri

Lymph Cancer Testing Market: Major Players
GE Healthcare, Siemens Healthineer, Abbott Laboratories, Canon Medical Systems, Agilent Technologies, MDx Health, Beckman Coulter, Myriad Genetics, Ambry Genetics, and Bio-Rad Laboratories among others.

Segment Covered in the Lymph Cancer Testing Market:
By Test Type
CT Scan & PET Scan lead with approximately 43.8% share, driven by high accuracy in staging and monitoring lymphoma progression. Blood Tests follow, supported by non-invasive biomarker analysis. Sentinel Lymph Node Biopsy holds significant share for precise nodal involvement assessment, while other advanced molecular tests are emerging rapidly.
By Disease Type
Non-Hodgkin Lymphoma dominates due to higher global incidence and diverse subtypes requiring comprehensive testing. Hodgkin Lymphoma accounts for the remaining share, benefiting from targeted diagnostic protocols.
By End-User
Hospitals lead as primary diagnostic and treatment centers. Diagnostic Centers follow with specialized testing services, while Research and Educational Institutions contribute through innovation and trials.

Regional Analysis
North America - Largest Share (approximately 42.1%)
North America dominates with advanced healthcare infrastructure, high adoption of innovative diagnostics, and strong R&D in the U.S. and Canada.
Europe - Significant Share
Europe grows through regulatory support and focus on precision oncology in countries like Germany, U.K., France, and Spain.
Asia-Pacific - Fastest Growing
Asia-Pacific expands rapidly due to rising cancer incidence, improving healthcare access, and investments in China, India, Japan, and South Korea.
South America - Emerging Share
South America sees steady growth led by Brazil and Argentina with increasing screening programs.
Middle East & Africa - Growing Share
Middle East & Africa advance with investments in oncology diagnostics in key nations.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=lymph-cancer-testing-market?sindhuri
(Purchase 2 or more Reports and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription
✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.